



## **Ci-Ca Dialysate K4** **Ci-Ca Dialysate K2**

New flexibility for the Ci-Ca Therapy



# Ci-Ca Dialysate K4

# Ci-Ca Dialysate K2

## New flexibility for the Ci-Ca CVVHD treatment

- Prevention of hypokalaemia
- Adaptation of the serum potassium level according to the conditions encountered during the course of a CRRT treatment.
- Increased treatment flexibility

The majority of patients with renal failure suffer from increased serum potassium levels, as the healthy organ is responsible for approx. 90% of the potassium excretion. At the start of a CRRT treatment, it is often necessary to normalise the patient's potassium levels. During the course of the treatment it is important to concentrate on the stabilisation of the potassium concentration within the physiological range of 3.5–4.5 mmol/L.

Now two CRRT solutions are available for local anticoagulation with citrate: the established Ci-Ca Dialysate K2 and the new Ci-Ca Dialysate K4 with 4 mmol/L potassium. These allow for the adjustment of the potassium concentration in the dialysate during the course of the treatment.



Thus, the two Ci-Ca Dialysates offer the ability to adapt the potassium levels to the requirements of the patient according to the situation and permit an adequate reaction to changes encountered during the course of the treatment. For the user, this presents new flexibility with the Ci-Ca CVVHD treatment.

Identification	Art. No.	Composition of the ready-to-use solutions:						
		Na <sup>+</sup> mmol/L	K <sup>+</sup> mmol/L	Ca <sup>++</sup> mmol/L	Mg <sup>++</sup> mmol/L	Cl <sup>-</sup> mmol/L	HCO <sub>3</sub> <sup>-</sup> mmol/L	Glucose g/L
Ci-Ca Dialysate K4	F00000431	133	4.0	0	0.75	118.5	20	1.0
Ci-Ca Dialysate K2	968 920 1	133	2.0	0	0.75	116.5	20	1.0
5-litre bag		<b>Other constituents:</b> water for injection, hydrochloric acid 25%, carbon dioxide						
Packaging: 2 bags per box								



Fresenius Medical Care